ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SILO vs SBFM // PIOTROSKI F-SCORE QUALITY

Silo Pharma Inc. (NASDAQ) VS. Sunshine Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: SILO 2 — SBFM 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: SBFM
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SILO VS. SBFM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SILO SBFM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 38.60% 33.80% +4.80 SILO /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -21.40% -13.60 SBFM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -17.20% -42.80 SBFM /operating-margins <GO>
Net Profit Margin -60.00% -16.50% -43.50 SBFM /net-margins <GO>
Revenue Growth (YoY) 0.00% 4.10% -4.10 SBFM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 3/9 4/9 -1.00 SBFM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.1 27.3 +6.81 SILO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.4M $2.5M -$155.0K SBFM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SILO REV SBFM REV SILO GROSS % SBFM GROSS % SILO FCF SBFM FCF
FY 2025 $72.1K $36.3M 38.6% 33.8% -$4.7M -$5.5M
FY 2024 $72.1K $34.9M 91.9% 30.6% -$3.8M -$14.2M
FY 2023 $72.1K $24.1M — — -$3.2M -$8.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SILO // BETA —
SBFM // BETA —